In this episode of Blunt Business, hosted by Cannabis Radio, Joshua S. Bauchner, Chair of the Cannabis, Hemp & Psychedelics Practice Group at Mandelbaum Barrett PC, dives into reports that President Trump may issue an executive order to reclassify cannabis from Schedule I to Schedule III.
Rescheduling vs. Declassification
While rescheduling would mark progress, Josh cautions that it may stall momentum toward full legalization, noting, “If we get reclassification, things will go dark for another 50 years before we can get to declassification.” Advocates argue that the current political moment should be used to push for complete declassification rather than settling for a halfway measure.
Medical and Business Implications
The discussion highlights how rescheduling could open doors for federally funded cannabis research and provide safer alternatives to opioids and PTSD treatments. At the same time, Josh warns that new federal requirements could complicate operations for dispensaries, potentially requiring pharmacists and stricter compliance measures.
The Marketplace Reality
Concerns about home grow and unregulated cannabis are addressed with a focus on consumer demand for safe, tested products. Josh stresses that regulated dispensaries will remain essential. “You can go in and buy something in the dispensary and be confident that what you’re getting is a safe and regulated product.”
Listen to the Full Episode
Joshua’s full interview on Blunt Business is available on Cannabis Radio.
For more information, you can reach Joshua Bauchner at jbauchner@mblawfirm.com or at 646-369-0250.